ALNYLAM PHARMACEUTICALS, INC. ALNY Income Statement

Alnylam pharmaceuticals, inc. (ALNY)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10	Sep'09	Jun'09
Revenues:
Total revenues
285,932	219,750	169,102	101,110	86,303	74,908	91,799	106,826	92,851	89,912	69,442	65,997	58,774	47,159	37,256	29,929	29,905	41,097	57,565	62,213	60,823	50,561	37,389	35,408	36,800	47,167	44,815	52,583	64,780	66,725	78,685	82,717	82,447	82,757	83,494	90,371	96,374	100,041	103,098	100,031	0	0	0
Operating costs and expenses:
Cost of goods sold
35,017	25,062	13,023	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
695,558	655,114	584,849	563,998	537,690	505,420	492,156	447,463	400,508	390,635	377,874	380,558	373,103	382,392	360,216	330,898	314,733	276,495	249,206	226,861	204,526	190,249	166,809	154,993	134,536	112,957	102,529	90,166	87,674	86,569	88,260	90,440	94,020	99,295	102,006	105,200	108,033	106,384	103,523	114,670	0	0	0
Selling, general and administrative
516,158	479,005	431,416	427,610	399,520	382,359	341,126	272,225	233,325	199,365	159,786	134,533	106,741	89,354	78,706	72,351	68,986	60,610	57,567	51,429	48,325	44,526	38,674	35,544	29,810	27,152	28,985	35,029	40,473	44,612	45,118	41,261	38,462	38,280	35,130	35,103	36,781	37,727	40,885	40,355	0	0	0
Total operating costs and expenses
1,246,733	1,159,181	1,030,816	1,001,083	942,359	889,581	833,419	719,688	633,833	590,000	537,660	515,091	479,844	471,746	438,922	403,249	383,719	337,105	306,773	278,290	248,961	455,541	426,249	411,303	389,002	140,109	196,514	190,195	193,147	196,181	133,378	131,701	132,482	137,575	137,136	140,303	144,814	144,111	144,408	155,025	0	0	0
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	220,766	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from operations
-960,801	-939,431	-861,714	-899,973	-856,056	-814,673	-741,620	-612,862	-540,982	-500,088	-468,218	-449,094	-421,070	-424,587	-401,666	-373,320	-353,814	-296,008	-249,208	-216,077	-188,138	-404,980	-388,860	-375,895	-352,202	-92,942	-151,699	-137,612	-128,367	-129,456	-54,693	-48,984	-50,035	-54,818	-53,642	-49,932	-48,440	-44,070	-41,310	-54,994	0	0	0
Other income:
Equity in loss of joint venture (Regulus Therapeutics Inc.)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,522	-4,595	-3,449	-3,322	-3,505	-3,467	-4,226	-7,133	-7,639	-7,859	-7,449	0	0	0
Interest income
31,403	33,448	36,766	33,673	30,993	29,262	22,926	19,426	15,902	12,236	10,200	9,108	8,623	8,308	7,725	7,131	6,658	5,859	5,023	4,166	3,240	2,559	2,064	1,601	1,178	1,069	1,006	977	978	977	991	995	1,046	1,205	1,441	1,778	2,097	2,305	2,869	3,725	0	0	0
Other income
34,297	11,308	-4,224	1,220	3,881	4,173	6,309	2,951	220	-3,022	-3,563	-2,729	-1,977	6,171	5,799	5,371	0	-	0	0	-	1,817	336	-200	-134	-47	146	155	145	331	168	-426	-421	-531	1,398	2,015	2,074	1,982	42	-2	0	0	0
Change in fair value of liability obligation
-	-	0	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on litigation settlement
-	-	0	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income
75,122	54,178	41,964	44,315	55,438	53,999	49,799	42,941	16,122	9,214	6,637	6,379	6,646	14,479	13,771	12,704	11,975	5,935	6,376	6,115	5,139	4,376	2,400	1,401	1,044	1,022	16,355	14,722	13,574	12,870	-3,436	-2,880	-2,697	-2,831	3,793	3,988	1,459	1,069	-4,948	-3,726	0	0	0
Loss before income taxes
-885,679	-885,253	-819,750	-855,658	-800,618	-760,674	-691,821	-569,921	-524,860	-490,874	0	0	0	-	-	-	-	-	-	-209,962	-182,999	-400,604	-386,460	-374,494	-351,158	-91,920	-135,344	-122,890	-114,793	-116,586	0	0	0	-	-	-	-	-43,001	-46,258	-58,720	0	0	0
Provision for income taxes
780	900	1,622	2,461	1,580	823	0	0	0	-	-	-	-	-	-	-	-	-	-	-22,024	-22,770	-40,209	-15,097	-17,434	-20,003	-2,695	0	0	0	-	-	-	-	-	-	-	-	514	-465	145	0	0	0
Net loss
-886,422	-886,116	-821,372	-858,119	-802,198	-761,497	-692,283	-569,938	-524,798	-490,874	-461,581	-442,715	-414,424	-410,108	-387,895	-360,616	-342,270	-290,073	-220,741	-187,938	-160,229	-360,395	-371,363	-357,060	-331,155	-89,225	-119,056	-108,872	-103,659	-106,014	-58,129	-51,864	-52,732	-57,649	-50,276	-46,669	-47,477	-43,515	-45,793	-58,865	0	0	0
Net loss per common share - basic and diluted (in dollars per share)
-1.62	-2.44	-1.92	-2.02	-1.73	-2.10	-2.43	-1.63	-1.41	-1.49	-1.34	-1.34	-1.25	-1.32	-1.21	-1.05	-1.21	0.00	-0.91	-0.85	-0.62	0.00	-0.58	-0.58	-3.70	0.00	-0.48	-0.29	-0.15	0.00	-0.38	-0.25	-0.25	0.00	-0.31	-0.33	-0.38	0.00	-0.23	-0.35	-0.29	-0.22	-0.55
Weighted-average common shares used to compute basic and diluted net loss per common share (in shares)
112,748	114,379	108,701	108,576	105,400	101,079	100,783	100,519	99,979	96,263	91,828	88,098	86,027	85,846	85,716	85,545	85,277	84,908	84,633	84,353	82,074	77,083	76,408	75,835	67,786	62,954	62,416	61,661	59,173	52,112	51,542	51,280	46,210	42,262	42,654	42,379	42,345	-	42,123	-	41,870	41,708	41,520
Statements of Comprehensive Loss
Net loss
-886,422	-886,116	-821,372	-858,119	-802,198	-761,497	-692,283	-569,938	-524,798	-490,874	-461,581	-442,715	-414,424	-410,108	-387,895	-360,616	-342,270	-290,073	-220,741	-187,938	-160,229	-360,395	-371,363	-357,060	-331,155	-89,225	-119,056	-108,872	-103,659	-106,014	-58,129	-51,864	-52,732	-57,649	-50,276	-46,669	-47,477	-43,515	-45,793	-58,865	0	0	0
Unrealized gain on marketable debt securities
4,243	558	951	1,416	2,000	1,220	349	152	-1,370	-2,886	-7,696	-6,690	-24,545	-30,833	-13,743	-40,948	-56,240	-44,394	-20,891	-1,140	29,436	31,127	-11,415	-6,147	4,209	4,055	27,060	28,192	20,858	15,827	259	184	-19	-879	-1,439	-1,532	-812	27	873	1,892	0	0	0
Foreign currency translation
-3	-343	2,281	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0
Defined benefit pension plans, net of tax
3,446	3,520	4,211	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification adjustment for realized loss on marketable securities included in net loss
-	-	-	-	-	-	-	-	-	-1,894	-1,733	-1,027	272	6,977	0	0	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-885,628	-889,421	-822,351	-860,143	-800,198	-760,277	-691,934	-569,786	-525,823	-491,866	-467,544	-448,378	-439,241	-447,918	-408,454	-407,674	-403,666	-334,467	-243,146	-191,159	-132,874	-331,349	-383,345	-363,207	-326,946	-85,170	-91,996	-80,680	-82,801	-90,187	-57,870	-51,680	-52,751	-58,528	-51,715	-48,201	-48,318	-43,517	-44,953	-57,029	0	0	0
Research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	12,328	12,851	0	0	0
General and administrative
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	7,816	8,194	0	0	0
Net product revenues
Total revenues
212,184	166,537	111,048	0	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net revenues from collaborations
Total revenues
73,748	53,213	46,439	24,053	47,477	62,373	70,511	84,834	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-